← Back to IPO List

Veradermics

Last updated: February 6, 2026
Ticker
MANE
Exchange
NYSE
IPO Date
Pending
Price Range
$14.00 - $16.00
Deal Size
$256 million
View MANE Live Chart on TradingViewAffiliate link — we may earn a commission.

Company Snapshot

Veradermics is a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for aesthetic and dermatological conditions. The company's initial focus is on creating better treatments for pattern hair loss, which affects approximately 50 million men and 30 million women in the United States. Veradermics aims to address the limitations of current treatment options by developing VDPHL01, an oral, non-hormonal treatment designed to improve patient satisfaction and outcomes.

Key Financials

Metric202420232022
RevenueNot providedNot providedNot provided
Adjusted Net Loss-$26.5M-$16.5MNot provided

S-1 Highlights

Market & Competition

The company operates in the biopharmaceutical market and competes with established players in the dermatological treatment space. Specific competitors were not mentioned in the filing.

Use of Proceeds

The company plans to use the proceeds from the IPO to advance its clinical programs and support its operational needs.

Key Risk Factors

  • ●The company has incurred recurring losses since its inception and expects to continue to generate operating losses for the foreseeable future.
  • ●As of December 31, 2024, the company had an accumulated deficit of $49.2 million, raising substantial doubt about its ability to continue as a going concern.

Reported Broker Availability

No broker information available yet

Check back later for updates

Reported by users or publicly disclosed. Information is for reference only.

Important Links & Filings

MANE Live Chart on TradingView →SEC S-1 Filing →
Important: Information presented on this website is aggregated from publicly available sources and voluntary user submissions. It is provided for informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. IPO access and availability may vary by broker and is not guaranteed; always verify details directly with your broker before making any investment decisions. We are not affiliated with, endorsed by, or acting on behalf of any broker-dealers, underwriters, or issuing companies. Some links to broker platforms may be affiliate links, and we may earn a commission if you open an account through those links. See full disclaimer for additional information.